UK markets closed

Sorrento Therapeutics, Inc. (0L85.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
1.0550+0.0400 (+3.94%)
At close: 05:09PM GMT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.96
52-week change 3N/A
S&P500 52-week change 3-7.13%
52-week high 31.0550
52-week low 31.0400
50-day moving average 3N/A
200-day moving average 3N/A

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 5111.3M
Implied shares outstanding 6N/A
Float 8459.61M
% held by insiders 11.31%
% held by institutions 135.26%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2021
Most-recent quarter (mrq)30 Sept 2022


Profit margin 0.00%
Operating margin (ttm)-669.16%

Management effectiveness

Return on assets (ttm)-36.87%
Return on equity (ttm)-378.92%

Income statement

Revenue (ttm)60.32M
Revenue per share (ttm)0.16
Quarterly revenue growth (yoy)44.30%
Gross profit (ttm)-167.05M
EBITDA -390.9M
Net income avi to common (ttm)-493.57M
Diluted EPS (ttm)-1.5270
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)117.86M
Total cash per share (mrq)0.25
Total debt (mrq)168.21M
Total debt/equity (mrq)129.19
Current ratio (mrq)0.88
Book value per share (mrq)0.29

Cash flow statement

Operating cash flow (ttm)-297.66M
Levered free cash flow (ttm)-233.08M